Literature DB >> 7872444

Activity of azithromycin as a blood schizonticide against rodent and human plasmodia in vivo.

S L Andersen1, A Ager, P McGreevy, B G Schuster, D Wesche, R Kuschner, C Ohrt, W Ellis, R Rossan, J Berman.   

Abstract

We compared the efficacy of azithromycin to the clinical antimalarial doxycycline in Plasmodium berghei-infected mice and in P. falciparum-infected Aotus monkeys. When mice were administered drug orally twice a day for three days, the minimum total dose of azithromycin that cured all mice was 768 mg/kg. Doxycycline at a dose of 1,536 mg/kg cured no mice. The efficacy of fast-acting blood schizonticides (quinine, halofantrine, artemisinin) against P. berghei was augmented by azithromycin. In monkey experiments in which there were two animals per experimental group, azithromycin (100 mg/kg/day for seven days) eliminated parasitemia; azithromycin (30 mg/kg/day) initially cleared 99.8-100% of the parasites with recrudescence in the one completely cleared case. Doxycycline (30 mg/kg/day) cleared 100% of the parasites with recrudescence in both cleared cases. Since azithromycin can be clinically administered at a somewhat higher daily dosage than doxycycline, the data suggest that it may be possible to replace drugs of the tetracycline class with azithromycin in combination with fast-acting blood schizonticides for the treatment of P. falciparum infection.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7872444     DOI: 10.4269/ajtmh.1995.52.159

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  12 in total

1.  In vitro activities of antibiotics against Plasmodium falciparum are inhibited by iron.

Authors:  B Pradines; C Rogier; T Fusai; J Mosnier; W Daries; E Barret; D Parzy
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  Potentiation of antifungal activity of amphotericin B by azithromycin against Aspergillus species.

Authors:  M H Nguyen; C J Clancy; Y C Yu; A S Lewin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-11       Impact factor: 3.267

3.  New potential antimalarial agents: therapeutic-index evaluation of pyrroloquinazolinediamine and its prodrugs in a rat model of severe malaria.

Authors:  Lisa H Xie; Qigui Li; Ai J Lin; Kirsten Smith; Jing Zhang; Donald S Skillman
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

4.  In vivo and in vitro antimalarial properties of azithromycin-chloroquine combinations that include the resistance reversal agent amlodipine.

Authors:  Marcus R Pereira; Philipp P Henrich; Amar Bir Singh Sidhu; David Johnson; Joel Hardink; Jeffrey Van Deusen; Jian Lin; Katrina Gore; Connor O'Brien; Mamadou Wele; Abdoulaye Djimde; Richa Chandra; David A Fidock
Journal:  Antimicrob Agents Chemother       Date:  2011-04-04       Impact factor: 5.191

5.  Pharmacodynamics of doxycycline in a murine malaria model.

Authors:  Kevin T Batty; Angela S F Law; Verity Stirling; Brioni R Moore
Journal:  Antimicrob Agents Chemother       Date:  2007-09-17       Impact factor: 5.191

6.  Assessment of azithromycin in combination with other antimalarial drugs against Plasmodium falciparum in vitro.

Authors:  Colin Ohrt; George D Willingmyre; Patricia Lee; Charles Knirsch; Wilbur Milhous
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

7.  A new in vivo screening paradigm to accelerate antimalarial drug discovery.

Authors:  María Belén Jiménez-Díaz; Sara Viera; Javier Ibáñez; Teresa Mulet; Noemí Magán-Marchal; Helen Garuti; Vanessa Gómez; Lorena Cortés-Gil; Antonio Martínez; Santiago Ferrer; María Teresa Fraile; Félix Calderón; Esther Fernández; Leonard D Shultz; Didier Leroy; David M Wilson; José Francisco García-Bustos; Francisco Javier Gamo; Iñigo Angulo-Barturen
Journal:  PLoS One       Date:  2013-06-25       Impact factor: 3.240

8.  Pharmaceutical development and optimization of azithromycin suppository for paediatric use.

Authors:  Tina Kauss; Alexandra Gaubert; Chantal Boyer; Boubakar B Ba; Muriel Manse; Stephane Massip; Jean-Michel Léger; Fawaz Fawaz; Martine Lembege; Jean-Michel Boiron; Xavier Lafarge; Niklas Lindegardh; Nicholas J White; Piero Olliaro; Pascal Millet; Karen Gaudin
Journal:  Int J Pharm       Date:  2012-12-03       Impact factor: 5.875

9.  Development of NIRS method for quality control of drug combination artesunate-azithromycin for the treatment of severe malaria.

Authors:  Chantal Boyer; Karen Gaudin; Tina Kauss; Alexandra Gaubert; Abdelhakim Boudis; Justine Verschelden; Mickaël Franc; Julie Roussille; Jacques Boucher; Piero Olliaro; Nicholas J White; Pascal Millet; Jean-Pierre Dubost
Journal:  J Pharm Biomed Anal       Date:  2012-04-23       Impact factor: 3.935

10.  Preliminary pharmaceutical development of antimalarial-antibiotic cotherapy as a pre-referral paediatric treatment of fever in malaria endemic areas.

Authors:  Alexandra Gaubert; Tina Kauss; Mathieu Marchivie; Boubakar B Ba; Martine Lembege; Fawaz Fawaz; Jean-Michel Boiron; Xavier Lafarge; Niklas Lindegardh; Jean-Louis Fabre; Nicholas J White; Piero L Olliaro; Pascal Millet; Luc Grislain; Karen Gaudin
Journal:  Int J Pharm       Date:  2014-04-13       Impact factor: 5.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.